Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD+ levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study

被引：139

作者：

Dellinger R.W. ^{[1
]}

Santos S.R. ^{[1
]}

Morris M. ^{[1
]}

Evans M. ^{[2
]}

Alminana D. ^{[1
]}

Guarente L. ^{[1
,3
]}

Marcotulli E. ^{[1
]}

机构：

[1] Elysium Health, Inc, New York, NY

[2] KGK Synergize London, London, ON

[3] Department of Biology, MIT, 77 Massachusetts avenue, 68-280, Cambridge, 02139, MA

来源：

npj Aging and Mechanisms of Disease | / 3卷 / 1期

关键词：

D O I：

10.1038/s41514-017-0016-9

中图分类号：

学科分类号：

摘要：

NRPT is a combination of nicotinamide riboside (NR), a nicotinamide adenine dinucleotide (NAD+) precursor vitamin found in milk, and pterostilbene (PT), a polyphenol found in blueberries. Here, we report this first-in-humans clinical trial designed to assess the safety and efficacy of a repeat dose of NRPT (commercially known as Basis). NRPT was evaluated in a randomized, double-blind, and placebo-controlled study in a population of 120 healthy adults between the ages of 60 and 80 years. The study consisted of three treatment arms: placebo, recommended dose of NRPT (NRPT 1X), and double dose of NRPT (NRPT 2X). All subjects took their blinded supplement daily for eight weeks. Analysis of NAD+ in whole blood demonstrated that NRPT significantly increases the concentration of NAD+ in a dose-dependent manner. NAD+ levels increased by approximately 40% in the NRPT 1X group and approximately 90% in the NRPT 2X group after 4 weeks as compared to placebo and baseline. Furthermore, this significant increase in NAD+ levels was sustained throughout the entire 8-week trial. NAD+ levels did not increase for the placebo group during the trial. No serious adverse events were reported in this study. This study shows that a repeat dose of NRPT is a safe and effective way to increase NAD+ levels sustainably. © 2017, The Author(s).

引用

共 34 条

[11]

Zhu X.H., Lu M., Lee B.Y., Ugurbil K., Chen W., In vivo NAD assay reveals the intracellular NAD contents and redox state in healthy human brain and their age dependences, Proc. Natl Acad. Sci. USA, 112, pp. 2876-2881, (2015)

[12]

Canto C., Menzies K.J., Auwerx J., NAD(+) Metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus, Cell Metab., 22, pp. 31-53, (2015)

[13]

Gomes A.P., Et al., Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging, Cell, 155, pp. 1624-1638, (2013)

[14]

Zhang H., Et al., NAD(+) repletion improves mitochondrial and stem cell function and enhances life span in mice, Science, 352, pp. 1436-1443, (2016)

[15]

Fang E.F., Et al., NAD+ replenishment improves lifespan and healthspan in Ataxia Telangiectasia models via mitophagy and DNA repair, Cell Metab., 24, pp. 566-581, (2016)

[16]

Scheibye-Knudsen M., Et al., A high-fat diet and NAD(+) activate Sirt1 to rescue premature aging in cockayne syndrome, Cell Metab., 20, pp. 840-855, (2014)

[17]

Canto C., Et al., The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity, Cell Metab., 15, pp. 838-847, (2012)

[18]

Yoshino J., Mills K.F., Yoon M.J., Imai S., Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice, Cell Metab., 14, pp. 528-536, (2011)

[19]

Frederick D.W., Et al., Loss of NAD homeostasis leads to progressive and reversible degeneration of skeletal muscle, Cell Metab, 24, pp. 269-282, (2016)

[20]

Hubbard B.P., Sinclair D.A., Measurement of sirtuin enzyme activity using a substrate-agnostic fluorometric nicotinamide assay, Methods Mol. Biol, 1077, pp. 167-177, (2013)

← 1 2 3 4 →